Merck cancels trial of melanoma treatment due to immune-mediated adverse events
An increased rate of discontinuation due to immune-mediated adverse events was seen in the trial's coformulation arm.
An increased rate of discontinuation due to immune-mediated adverse events was seen in the trial's coformulation arm.
The FDA granted de novo classification to the Symani Surgical System for soft tissue manipulation in microsurgery in April 2024.
The pharmaceutical industry continues to be a hotbed of patent innovation. Activity is driven by the evolution of new treatment...
“Defensibility” key for AI-centric small biotechs seeking investment
Klineo wins €2m to advance AI patient recruitment platform
Hyperfine starts enrolment in portable imaging workflow study
Acarix starts clinical workflow study for its AI-powered cardiac diagnostic